NVP is advancing a new generation of Targeted Nanosphere (TNS) based products incorporating our core and highly optimized HPLN (Hybrid Polymerized Liposomal Nanoparticle) IP technology. These TNS may provide a vast improvement in flexibility and choice for patients restricted by current treatment options including antibody, immunotherapy and ADC based products. Both by repositioning existing therapies such as chemotherapeutics and by truly targeting and optimising the delivery of emerging candidates including small molecules and nucleic acid based therapeutics.
Our current main candidate focus is in oncology with our lead candidate NV103 approaching pediatric (Ewing Sarcoma) and adult (Glioblastoma) IND status, but it is already clear that once clinically validated TNS technology can be applied to other oncology challenges such as pancreatic and liver cancer plus other non-oncological sectors such as neurology, as opportunities present. We also have other candidates such as NV101, NV102 and NV201 plus a rapidly progressing pilot programs in nucleic acid delivery and in trans-BBB (blood brain barrier) related delivery therapy.